News: Astellas Pharma Inc (ALPMF.PK)

ALPMF.PK on OTC Markets Group

15.24USD
7 Oct 2014
Price Change (% chg)

$0.68 (+4.67%)
Prev Close
$14.56
Open
$15.05
Day's High
$15.24
Day's Low
$14.95
Volume
4,800
Avg. Vol
2,219
52-wk High
$15.24
52-wk Low
$9.79

Search Stocks
Select another date:

Wed, Sep 10 2014

U.S. FDA approves expanded use of Medivation prostate cancer drug

- U.S. health regulators approved the use of Medivation Inc's and Astellas Pharma Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the companies said on Wednesday, significantly expanding the potential patient population for the oral medicine.

UPDATE 1-U.S. FDA approves expanded use of Medivation prostate cancer drug

Sept 10 - U.S. health regulators approved the use of Medivation Inc's and Astellas Pharma Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the companies said on Wednesday, significantly expanding the potential patient population for the oral medicine.

Select another date:

Press Releases

Search Stocks